Guardant Health Soars 6.1% on Raised Revenue Outlook and Shelf Registration

Guardant Health (GH) shares rose by 6.1% after the company raised its revenue outlook for 2026 and filed an omnibus shelf registration. This update ties the investment case more tightly to sustained screening growth and payer uptake.

The company reported Q2 2026 results showing sales of $334.98 million and a net loss of $120.14 million, alongside higher full-year revenue guidance of $1.34, $1.36 billion. This is supported by surging Shield screening volumes, including new UnitedHealth coverage and recent FDA approvals.

The increased 2026 revenue guidance affects the investment narrative, with the near-term catalyst being accelerating Shield adoption. However, the key risk remains persistent net losses and ongoing cash burn.